Clene reports FY2024 net loss $39.4M ($5.67/sh); plans NDA for CNM-Au8 in ALS in H2 2025

Clene Inc.

Net loss $39.4M ($5.67/sh) vs. $49.5M ($9.43/sh) in FY2023.
Cash and marketable securities $12.2M at Dec 31, 2024; expected to fund ops into Q2 2025.
R&D expense $20.1M, down 25% YoY; G&A $13.3M, down 8%.
Planning NDA submission for CNM-Au8 in ALS in H2 2025; confirmatory Phase 3 RESTORE-ALS starts mid-2025.
Secured new $10M debt facility (12% interest, convertible at $5.67) replacing $7.85M Avenue debt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.